Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population

Mojumdar, Kamalika; Vajpayee, Madhu; Chauhan, Neeraj K.; Mendiratta, Sanjay
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p416
Academic Journal
Background: Timely access to antiretroviral therapy is a key to controlling HIV infection. Late diagnosis and presentation to care diminish the benefits of antiretrovirals and increase risk of transmission. We aimed to identify late presenters in patients sent for first CD4 T cell count after HIV diagnosis, for therapy initiation evaluation. Further we aimed at identifying patient factors associated with higher risk of late presentation. Methods: Retrospective data collection and analysis was done for 3680 subjects visiting the laboratory for CD4 T cell counts between 2001 and 2007. We segregated the patients on basis of their CD4 T cell counts after first HIV diagnosis. Factors associated with risk of late presentation to CD4 T cell counts after HIV diagnosis were identified using univariate analysis, and the strength of association of individual factor was assessed by calculation of odds ratios. Results: Of 3680 subjects, 2936 (83.37%) were defined as late presenters. Late testing varied among age groups, transmission categories, and gender. Males were twice as likely to present late as compared to females. We found significant positive association of heterosexual transmission route (p < 0.001), and older age groups of 45 years and above (p = 0.0004) to late presentation. Female sex, children below 14 years of age and sexual contact with HIV positive spouse were associated with significantly lower risks to presenting late. Intravenous drug users were also associated with lower risks of late presentation, in comparison to heterosexual transmission route. Conclusions: The study identifies HIV infected population groups at a higher risk of late presentation to care and treatment. The risk factors identified to be associated with late presentation should be utilised in formulating targeted public health interventions in order to improve early HIV diagnosis.


Related Articles

  • Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. Zhiqing Zhang; Shaowei Li; Ying Gu; Ningshao Xia // International Journal of Molecular Sciences;Nov2016, Vol. 17 Issue 11, p1901 

    Human immunodeficiency virus type 1 (HIV-1) infection causes acquired immune deficiency syndrome (AIDS), a global epidemic for more than three decades. HIV-1 replication is primarily controlled through antiretroviral therapy (ART) but this treatment does not cure HIV-1 infection. Furthermore,...

  • Perspectives on HAART: switch maintenance therapy. Leen, C. L. S. // International Journal of STD & AIDS;Sep2003, Vol. 14 Issue 9, p577 

    Switch studies have been carried out to explore changes in side effects in adherence. Discontinuing the protease inhibitor (PI) component of highly active antiretroviral therapy (HAART) regimen is often associated with improved adherence and improved quality of life. Following switching from a...

  • Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. Kimmel, April D.; Resch, Stephen C.; Anglaret, Xavier; Daniels, Norman; Goldie, Sue J.; Danel, Christine; Wong, Angela Y.; Freedberg, Kenneth A.; Weinstein, Milton C. // Cost Effectiveness & Resource Allocation;2012, Vol. 10 Issue 1, p12 

    Background: In resource-limited settings, HIV budgets are flattening or decreasing. A policy of discontinuing antiretroviral therapy (ART) after HIV treatment failure was modeled to highlight trade-offs among competing policy goals of optimizing individual and population health outcomes....

  • Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges? Boullie, A.; Ford, N. // Sexually Transmitted Infections;Dec2007, Vol. 83 Issue 8, p503 

    The article comments on the need for cost-effective interventions to reduce HIV in developing countries. There have been concerns on the promotion of widespread access to antiretroviral therapy in Southern Africa. Data on the effectiveness of the interventions since year 2000 have been compiled....

  • Maraviroc.  // AHFS Consumer Medication Information;Jun2020, p1 

    Maraviroc is used with other medications to treat human immunodeficiency virus (HIV) in patients with or without acquired immunodeficiency syndrome (AIDS). Maraviroc is in a class of antiviral medications called CCR5 co-receptor antagonists. It works by slowing the spread of HIV in the body....

  • Clinical Experience and Choice of Drug Therapy for Human Immunodeficiency Virus Disease. Brosgart, Carol L.; Mitchell, Thomas F.; Coleman, Rebecca L.; Dyner, Toby; Stephenson, Kathryn E.; Abrams, Donald I. // Clinical Infectious Diseases;1/1/1999, Vol. 28 Issue 1, p14 

    Studies the relationship between clinical experience and choice of drug therapy for human immunodeficiency virus disease. Likelihood that the provider with report prescribing high active antiretroviral therapy and multidrug combinations for treatment of opportunistic infections.

  • Treating 3 million people living with HIV/AIDS by 2005.  // WHO Drug Information;2004, Vol. 18 Issue 1, p11 

    Presents news briefs related to global HIV/AIDS treatment as of 2004. World Health Organization's launching of a strategy for treating three million people with HIV/AIDS by 2005; Mechanism for expanding access to quality and effective treatment for HIV/AIDS under the AIDS medicines and...

  • Implementation of a standardized HIV patient monitoring system in Guyana. Halpern, Mina; Lachmansingh, Bendita; Minior, Thomas; Hasbrouck, La Mar; Persaud, Nicholas; Foo, Astrid // Revista Panamericana de Salud Publica;Aug2010, Vol. 28 Issue 2, p107 

    Objective. To describe the process used to implement a comprehensive, standardized, and reliable national system for data collection for HIV care and treatment in Guyana; to provide examples of the program-level data resulting from implementation; and to highlight the monitoring benefits for...

  • The Case for Earlier Treatment of HIV Infection. Holmberg, Scott D.; Palella Jr., Frank J.; Lichtenstein, Kenneth A.; Havlir, Diane V. // Clinical Infectious Diseases;12/1/2004, Vol. 39 Issue 11, p1699 

    Current US guidelines advise that antiretroviral therapy for asymptomatic HIV patients should definitely be started for those who have CD4+ cell counts of >200 cells/μL, but antiretroviral therapy is often not started at CD4+ cell counts much above that level. Guidelines advocating later...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics